Technology stocks bounced Tuesday after three rocky trading sessions, spurred by hopes that the U.S. may negotiate aggressive tariffs with world leaders.
Related Posts
Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
CVS gets an upgrade to buy from Leerink Partners after pharmacy operator’s strong earnings
CVS Health has more room to run even as the broader health care segment remains troubled, according to Leerink Partners.
Charts suggest S&P 500 sell-off will continue until this level, says Carter Worth
Worth breaks down the trendlines on the S&P 500.